TABLE 1.

Characteristics of 17 blaVIM-1-containing K. pneumoniae clinical isolates and 6 E. coli transconjugants

IsolateaHospitalIsolation date (day-mo-yr)PFGE typeEtest MICs (μg/ml) of β-lactamsbOther resistance markersc
PIPTZPCTXCAZATMIPMIPM-EMEM
Kp1I17-09-02A>25625612825625632<132Gm, Net, Tb, An, Sxt, C
    Ec(trc-1)>256128128>25621<10.25Gm, Net, Tb, An, Sxt, C
Kp2I18-10-02A>256256>256>256>2568<14Gm, Net, Tb, An, Sxt, C
    Ec(trc-2)1281281283220.5<10.12Gm, Net, Tb, An, Sxt, C
Kp3I06-11-02A12812812825612816<116Gm, Net, Tb, An, Sxt, C
Kp4I10-11-02A>256256641286432<132Gm, Net, Tb, An, Sxt, C
Kp5I17-11-02B>25625664>256>2564<11Gm, Net, Tb, An, Sxt
Kp6I12-12-02A2561281282561288<14Gm, Net, Tb, An, Sxt, C
Kp7II10-10-02C>256>2562562560.1232<116Net, Tb, An, Sxt
Kp8II11-10-02C>256>2561282560.2532<1>32Net, Tb, An, Sxt
    Ec(trc-8)>25625664>2560.124<10.5Net, Tb, An, Sxt
Kp9II22-10-02C>25625664>2560.516<18Net, Tb, An, Sxt
Kp10II16-11-02C>256256642560.532<18Net, Tb, An, Sxt
Kp11II27-11-02C1>256>256256>2560.124<11Net, Tb, An, Sxt
    Ec(trc-11)>25625632>2560.062<10.25Net, Tb, An, Sxt
Kp12III09-11-02D>256>256128>2560.516<18Net, Tb, An, Sxt
Kp13III28-11-02C>25625664>2560.128<12Net, Tb, An, Sxt
    Ec(trc-13)>25612832>2560.062<10.5Net, Tb, An, Sxt
Kp14III05-12-02C>25625632>2560.58<18Net, Tb, An, Sxt
Kp15III05-12-02C>256256642560.254<12Net, Tb, An, Sxt
Kp16III05-12-02C>256256128>256324<12Net, Tb, An, Sxt
    Ec(trc-16)256128322560.122<10.25Net, Tb, An, Sxt
Kp17III15-12-02C256128641280.258<18Net, Tb, An, Sxt
E. coli 14R0.50.5<0.030.06<0.030.03<0.03
  • a K. pneumoniae clinical isolates Kp1 to Kp17 and six E. coli transconjugants [Ec(trc-1), Ec(trc-2), etc.] and E. coli strain 14R.

  • b PIP, piperacillin; TZP, piperacillin-tazobactam (inhibitor fixed at 4 μg/ml); CTX, cefotaxime; CAZ, ceftazidime; ATM, aztreonam; IPM, imipenem; IPM-E, imipenem-EDTA (inhibitor fixed at 320 μg/ml); MEM, meropenem.

  • c Gm, gentamicin; Tb, tobramycin; Net, netilmicin; An, amikacin; Sxt, co-trimoxazole; C, chloramphenicol.